BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38058346)

  • 1. Relamorelin in Gastroparesis and Diabetic Gastroparesis: A Meta-Analysis on Its Efficacy and Safety.
    Patel A; Arora GS; Roknsharifi M; Javed H; Kaur P
    Cureus; 2023 Nov; 15(11):e48303. PubMed ID: 38058346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.
    Camilleri M; McCallum RW; Tack J; Spence SC; Gottesdiener K; Fiedorek FT
    Gastroenterology; 2017 Nov; 153(5):1240-1250.e2. PubMed ID: 28760384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.
    Lembo A; Camilleri M; McCallum R; Sastre R; Breton C; Spence S; White J; Currie M; Gottesdiener K; Stoner E;
    Gastroenterology; 2016 Jul; 151(1):87-96.e6. PubMed ID: 27055601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist.
    Camilleri M; Acosta A
    Neurogastroenterol Motil; 2015 Mar; 27(3):324-32. PubMed ID: 25545036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relamorelin for the treatment of gastrointestinal motility disorders.
    Chedid V; Camilleri M
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1189-1197. PubMed ID: 28847163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers.
    Nelson AD; Camilleri M; Acosta A; Busciglio I; Linker Nord S; Boldingh A; Rhoten D; Ryks M; Burton D
    Neurogastroenterol Motil; 2016 Nov; 28(11):1705-1713. PubMed ID: 27283792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data.
    Camilleri M; Lembo A; McCallum R; Tourkodimitris S; Kemps L; Miller MB; Bertelsen K; Iacob A
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1139-1148. PubMed ID: 32301137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Ghrelin Agonists in Patients with Diabetic Gastroparesis: A Systematic Review and Meta-Analysis.
    Hong SW; Chun J; Kim J; Lee J; Lee HJ; Chung H; Cho SJ; Im JP; Kim SG; Kim JS
    Gut Liver; 2020 Sep; 14(5):589-600. PubMed ID: 31816671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment With a Ghrelin Agonist in Outpatient Women With Anorexia Nervosa: A Randomized Clinical Trial.
    Fazeli PK; Lawson EA; Faje AT; Eddy KT; Lee H; Fiedorek FT; Breggia A; Gaal IM; DeSanti R; Klibanski A
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29325236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial.
    Acosta A; Camilleri M; Kolar G; Iturrino J; Szarka LA; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR; Spence SC; Gottesdiener K; Bouras EP; Vazquez-Roque MI
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2312-9.e1. PubMed ID: 26001337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Highly Selective 5-Hydroxytryptamine Receptor 4 Agonists for Diabetic and Idiopathic Gastroparesis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Patel P; Zaher EA; Khataniar H; Ebrahim MA; Loganathan P
    Cureus; 2024 Jan; 16(1):e51851. PubMed ID: 38327939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Approaches to Diabetic Gastroparesis: A systematic review of randomised clinical trials.
    Asha MZ; Khalil SFH
    Sultan Qaboos Univ Med J; 2019 Nov; 19(4):e291-e304. PubMed ID: 31897312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acupuncture for symptomatic gastroparesis.
    Kim KH; Lee MS; Choi TY; Kim TH
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009676. PubMed ID: 30560568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis.
    Ejskjaer N; Wo JM; Esfandyari T; Mazen Jamal M; Dimcevski G; Tarnow L; Malik RA; Hellström PM; Mondou E; Quinn J; Rousseau F; McCallum RW
    Neurogastroenterol Motil; 2013 Feb; 25(2):e140-50. PubMed ID: 23279217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease.
    Zatorski H; Mosinska P; Storr M; Fichna J
    J Physiol Pharmacol; 2017 Dec; 68(6):797-805. PubMed ID: 29550791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus.
    Shin A; Camilleri M; Busciglio I; Burton D; Smith SA; Vella A; Ryks M; Rhoten D; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1453-1459.e4. PubMed ID: 23639598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists.
    Petri M; Singh I; Baker C; Underkofler C; Rasouli N
    J Diabetes Complications; 2021 Feb; 35(2):107733. PubMed ID: 32948398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study.
    Murray CD; Martin NM; Patterson M; Taylor SA; Ghatei MA; Kamm MA; Johnston C; Bloom SR; Emmanuel AV
    Gut; 2005 Dec; 54(12):1693-8. PubMed ID: 16085693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Promotility Agents on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis.
    Vijayvargiya P; Camilleri M; Chedid V; Mandawat A; Erwin PJ; Murad MH
    Gastroenterology; 2019 May; 156(6):1650-1660. PubMed ID: 30711628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis.
    Abell TL; Kuo B; Esfandyari T; Pfeifer ND; Grimaldi M; Renzulli C; Tacchi R; Zhou K; Barnes CN; Nguyen DD; Nguyen L; Talley NJ; McCallum R
    Neurogastroenterol Motil; 2023 Apr; 35(4):e14523. PubMed ID: 36624727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.